Nonetheless, considering the effect of myostatin on muscle growth, inhibition of myostatin has been considered a therapeutic target in the treatment of muscle-degenerative and wasting conditions, such as muscular dystrophies, and clinical trials have been designed to increase muscle mass and strength in several of the most common forms of adult muscular dystrophy. This evidence concerns the gene MSTN and muscular dystrophy.